Evidence map›Paper›PMID 25573908›Full record

Trial reportJournal of the American Society of Nephrology : JASN2015

Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.

Jeffrey B Kopp, Cheryl A Winkler, Xiongce Zhao, Milena K Radeva, Jennifer J Gassman, Vivette D D'Agati, Cynthia C Nast, Changli Wei, Jochen Reiser, Lisa M Guay-Woodford and 8 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 5 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 5 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Interventions for focal segmental glomerulosclerosis in adults.The Cochrane database of systematic reviews · 2022
    Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Trial
  7. Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021
    Trial
  8. Article
  9. Update on APOL1 and chronic kidney diseases in children.Pediatric nephrology (Berlin, Germany) · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 3 countries.

Jeffrey B KoppKidney Disease Section, jbkopp@nih.gov.
Cheryl A WinklerBasic Research Laboratory, Center for Cancer Research, National Cancer Institute, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland;
Xiongce ZhaoBiostatistics Core, and.
Milena K RadevaDepartment of Quantitative Heath Sciences, Cleveland Clinic, Cleveland, Ohio;
Jennifer J GassmanDepartment of Quantitative Heath Sciences, Cleveland Clinic, Cleveland, Ohio;
Vivette D D'AgatiDepartment of Pathology, Columbia University Medical Center, New York, New York;
Cynthia C NastDepartment of Pathology, Cedars-Sinai Medical Center, Los Angeles, California;
Changli WeiDepartment of Medicine, Rush University Medical Center, Chicago, Illinois;
Jochen ReiserDepartment of Medicine, Rush University Medical Center, Chicago, Illinois;
Lisa M Guay-WoodfordCenter for Translational Science, Children's National Health System, Washington, DC;
Martin R PollakBeth Israel Deaconess Medical Center and.
Friedhelm HildebrandtChildren's Hospital Boston, Harvard Medical School, Boston, Massachusetts;
Marva Moxey-MimsDivision of Kidney, Urology and Hematology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland;
Debbie S GipsonDepartment of Pediatrics and Communicable Disease, University of Michigan, Ann Arbor, Michigan;
Howard TrachtmanDepartment of Pediatrics, New York University School of Medicine, New York, New York;
Aaron L FriedmanDepartment of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota; and.
Frederick J KaskelChildren's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York.
FSGS-CT Study Consortium
Cleveland Clinic · USKidney Care UK · GBLeidos (United States) · USBoston Children's Hospital · USCedars-Sinai Medical Center · USCenter for Cancer Research · USChildren's Hospital at Montefiore · USColumbia University Irving Medical Center · USHadassah Medical Center · ILNational Institutes of Health · USNew York University · USRush University Medical Center · USUniversity of Michigan–Ann Arbor · US

Funding

Focal Segmental Glomerulosclerosis: Genetics & MechanismsZIADK043308 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI KOPP, JEFFREY BURNETT · 2009 to 2024
$15.7M
Genetics of Renal Disease in African AmericansZIABC010022 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WINKLER, CHERYL · 2009 to 2022
$8.9M
Identification and function of new genes causing childhood nephrotic syndromeR01DK076683 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HILDEBRANDT, FRIEDHELM · 2007 to 2021
$5.3M
APOL1 variants: Understanding the basis of disparities in rates of kidney diseaseR01MD007092 · NIMHD · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FRIEDMAN, DAVID J, POLLAK, MARTIN R. · 2012 to 2021
$4.3M
Role of Circulating suPAR in FSGSR01DK101350 · NIDDK · RUSH UNIVERSITY MEDICAL CENTER · PI REISER, JOCHEN · 2013 to 2017
$2.6M
Intramural NIH HHSNIDDK NIH HHS R01 DK076683NIDDK NIH HHS R01 DK101350NIMHD NIH HHS R01 MD007092PHS HHS HHSN26120080001E
6 · The paper itself

Abstract

Genetic variants in apolipoprotein L1 (APOL1) confer risk for kidney disease. We sought to better define the phenotype of APOL1-associated nephropathy. The FSGS Clinical Trial involved 138 children and young adults who were randomized to cyclosporin or mycophenolate mofetil plus pulse oral dexamethasone with a primary outcome of proteinuria remission. DNA was available from 94 subjects who were genotyped for APOL1 renal risk variants, with two risk alleles comprising the risk genotype. Two APOL1 risk alleles were present in 27 subjects, of whom four subjects did not self-identify as African American, and 23 of 32 (72%) self-identified African Americans. Individuals with the APOL1 risk genotype tended to present at an older age and had significantly lower baseline eGFR, more segmental glomerulosclerosis and total glomerulosclerosis, and more tubular atrophy/interstitial fibrosis. There were differences in renal histology, particularly more collapsing variants in those with the risk genotype (P=0.02), although this association was confounded by age. APOL1 risk genotype did not affect response to either treatment regimen. Individuals with the risk genotype were more likely to progress to ESRD (P<0.01). In conclusion, APOL1 risk genotypes are common in African-American subjects with primary FSGS and may also be present in individuals who do not self-identify as African American. APOL1 risk status is associated with lower kidney function, more glomerulosclerosis and interstitial fibrosis, and greater propensity to progress to ESRD. The APOL1 risk genotype did not influence proteinuria responses to cyclosporin or mycophenolate mofetil/dexamethasone.

Indexed as

AdolescentAdultApolipoprotein L1ApolipoproteinsChildCyclosporinsDexamethasoneFemaleFollow-Up StudiesGene Expression RegulationGenotypeGlomerulosclerosis, Focal SegmentalHumansKidney Function TestsLipoproteins, HDLMaleAPOL1 protein, humanApolipoprotein L1ApolipoproteinsCyclosporinsDexamethasoneLipoproteins, HDLMycophenolic AcidcyclosporinFSGSgenetic renal disease

Identifiers

PMID25573908
PMCPMC4446865
OpenAlexW2095763846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.